Rodgers Brothers’s Regeneron Pharmaceuticals REGN Stock Holding History

Rodgers Brothers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-250	Closed	-$263K	–	239
2024 Q3	$263K	Hold	250	–	–	0.03%	211
2024 Q2	$263K	Hold	250	–	–	0.04%	212
2024 Q1	$241K	Hold	250	–	–	0.03%	222
2023 Q4	$220K	Hold	250	–	–	0.03%	220
2023 Q3	$206K	Buy	+250	New	+$196K	0.04%	214
2023 Q2	–	Sell	-250	Closed	-$205K	–	216
2023 Q1	$205K	Buy	+250	New	+$189K	0.04%	205
2022 Q2	–	Sell	-300	Closed	-$210K	–	198
2022 Q1	$210K	Buy	+300	New	+$190K	0.04%	192
2016 Q1	–	Sell	-450	Closed	-$244K	–	176
2015 Q4	$244K	Sell	450 -50	-10%	-$27.1K	0.11%	142
2015 Q3	$233K	Hold	500	–	–	0.12%	139
2015 Q2	$255K	Hold	500	–	–	0.12%	136
2015 Q1	$226K	Hold	500	–	–	0.11%	145
2014 Q4	$205K	Buy	+500	New	+$197K	0.1%	144

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rodgers Brothers's REGN Position: Q4 2024 in Review

Rodgers Brothers sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 250 shares — an estimated $263K sold.

Rodgers Brothers first reported a position in REGN in Q4 2014 and held it in 12 quarters. The position peaked at $263K in Q3 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Rodgers Brothers reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Rodgers Brothers sold 250 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $263K.
Rodgers Brothers first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 12 quarters.
Rodgers Brothers's Regeneron Pharmaceuticals position peaked at $263K in Q3 2024.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Rodgers Brothers's 13F filing for Q4 2024, filed 12 Feb 2025.